Anthropic Launches Internal Drug Discovery Program via Mithril Medicine Acquisition and Partners With Six Biotechs Using Claude
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
Context
Moving beyond third party software licensing into direct preclinical drug programs and biotech company creation shows frontier AI labs are integrating vertically into wet lab therapeutics to capture value across target discovery, antibody engineering, and regulatory filings.
Over the past year, Anthropic has expanded its scientific computing footprint through the rollout of its Claude Science workbench and the Life Sciences Verification Program, which grants vetted biomedical researchers access to frontier Claude models with tailored biosecurity guardrails. While AI in pharmaceuticals has historically focused on initial molecular structure prediction, operational bottlenecks across wet lab optimization, manufacturing quality control, and clinical trial filings continue to slow drug approval timelines.
Deep dive
On October 27, Anthropic's Science team published technical reports detailing several months of deep drug development partnerships with six life sciences organizations alongside the launch of Anthropic's own internal therapeutics programs. Anthropic disclosed that it has acquired Mithril Medicine, a one person biotechnology company founded by Cody Tranbarger that develops treatments for two rare childhood forms of muscular dystrophy. Using Claude to coordinate contracts, logistics, and experiments across 11 external contract research laboratories, Tranbarger advanced a muscular dystrophy candidate from initial concept to promising efficacy in mice in under 18 months, and now continues the program inside Anthropic with human clinical trials targeted for late 2028.
Across its six external partners, Anthropic embedded researchers directly into preclinical and clinical workflows. At Generate Biomedicines, six scientists used Claude Code to design a CAR T cell therapy genetic component roughly 70 percent shorter than standard sequences, enabling immune cells to express 10 times more cancer spotting receptors and stay active longer against solid tumors. At Divergence Labs, Claude autonomously generated roughly 35,000 dual arm antibody designs in one month to detach IgE molecules from immune cells for food allergies, yielding 20 active hits including three that outperformed standard medication.
Connected to BigHat Biosciences' automated lab system Reccy across 1,010 antibody variants tested in 10 weeks, Claude helped identify flawed stability metrics and produced leads with 10x tighter binding, 18 degree Celsius higher thermal stability, and 100x slower clumping. At Enveda, Claude audited 1,061 pages of manufacturing records to catch all 11 human identified errors plus seven missed defects while cutting review time by 89 percent and drafting a three month regulatory filing in four hours. Meanwhile, The Column Group is incubating a Claude native biotech called Pleiades evaluated on 45 target disease pairs, and Bristol Myers Squibb is using Claude to model early stage clinical trial success probabilities.
What to expect next
Anthropic plans to expand its Bristol Myers Squibb collaboration across portfolio level clinical trial planning in 2027 while advancing its internal muscular dystrophy candidates acquired through Mithril Medicine toward human clinical trials by late 2028. Through its open call for guest life sciences investigators, Claude Science credits, and the Life Sciences Verification Program, watch for more biotechnology startups to adopt Pleiades style AI native operating models where small teams orchestrate external wet labs through Claude.